Integrated BioPharma, Inc.

OTCPK:INBP Stock Report

Market Cap: US$9.6m

Integrated BioPharma Management

Management criteria checks 4/4

Integrated BioPharma's CEO is Riva Sheppard, appointed in May 2019, has a tenure of 5.58 years. total yearly compensation is $343.55K, comprised of 78% salary and 22% bonuses, including company stock and options. directly owns 4.39% of the company’s shares, worth $422.63K. The average tenure of the management team and the board of directors is 5.6 years and 23 years respectively.

Key information

Riva Sheppard

Chief executive officer

US$343.6k

Total compensation

CEO salary percentage78.0%
CEO tenure5.6yrs
CEO ownership4.4%
Management average tenure5.6yrs
Board average tenure23yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Riva Sheppard's remuneration changed compared to Integrated BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$430k

Jun 30 2024US$344kUS$268k

US$112k

Mar 31 2024n/an/a

-US$116k

Dec 31 2023n/an/a

-US$385k

Sep 30 2023n/an/a

-US$58k

Jun 30 2023US$306kUS$242k

-US$34k

Mar 31 2023n/an/a

US$1m

Dec 31 2022n/an/a

US$2m

Sep 30 2022n/an/a

US$3m

Jun 30 2022US$278kUS$230k

US$4m

Mar 31 2022n/an/a

US$7m

Dec 31 2021n/an/a

US$7m

Sep 30 2021n/an/a

US$7m

Jun 30 2021US$245kUS$219k

US$8m

Mar 31 2021n/an/a

US$5m

Dec 31 2020n/an/a

US$5m

Sep 30 2020n/an/a

US$5m

Jun 30 2020US$226kUS$214k

US$4m

Mar 31 2020n/an/a

US$3m

Dec 31 2019n/an/a

US$3m

Sep 30 2019n/an/a

US$2m

Jun 30 2019US$202kUS$178k

US$2m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

US$2m

Sep 30 2018n/an/a

US$1m

Jun 30 2018US$183kUS$176k

US$679k

Compensation vs Market: Riva's total compensation ($USD343.55K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Riva's compensation has been consistent with company performance over the past year.


CEO

Riva Sheppard (57 yo)

5.6yrs

Tenure

US$343,553

Compensation

Mrs. Riva Kay Sheppard has been Co-Chief Executive Officer of Integrated Biopharma Inc. since May 1, 2019. Mrs. Sheppard served as Executive Vice President at Integrated Biopharma Inc. (aka: Integrated Bio...


Leadership Team

NamePositionTenureCompensationOwnership
Riva Sheppard
Co-CEO & Director5.6yrsUS$343.55k4.39%
$ 422.6k
Christina Kay
Co-CEO & Director5.6yrsUS$343.55k4.39%
$ 422.6k
Dina Masi
Senior VP19.1yrsUS$357.08k0.70%
$ 67.5k
Jamie Levey
Head of Investor Relationsno datano datano data

5.6yrs

Average Tenure

57yo

Average Age

Experienced Management: INBP's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Riva Sheppard
Co-CEO & Director33.6yrsUS$343.55k4.39%
$ 422.6k
Christina Kay
Co-CEO & Director30yrsUS$343.55k4.39%
$ 422.6k
Eric Friedman
Independent Director4.1yrsUS$23.80k0%
$ 0
Damon DeSantis
Director2.5yrsUS$20.80k0.033%
$ 3.2k
Robert Canarick
Independent Director30yrsUS$23.80k0.20%
$ 18.8k
William Milmoe
Director16yrsUS$23.80k0.29%
$ 28.2k

23.0yrs

Average Tenure

67yo

Average Age

Experienced Board: INBP's board of directors are seasoned and experienced ( 23 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Integrated BioPharma, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution